SHARE
COPY LINK

VACCINES

EU launches ‘vaccine tracker’ and shifts strategy away from AstraZeneca

The EU's disease agency has launched a Covid-19 vaccine tracking tool, providing an overview of countries' efforts in the rollout of inoculations across Europe. It came as the EU Commission said it was shifting its strategy away from relying on the AstraZeneca vaccine.

EU launches 'vaccine tracker' and shifts strategy away from AstraZeneca
Photo: Ishara S Kodikara/AFP and ECDC (edited by The Local)

The first set of data was available on the website of the European Centre for Disease Prevention and Control (ECDC), covering the 27-nation bloc plus Iceland, Liechtenstein and Norway. 

However it was still incomplete on Monday, as some countries, such as France had yet to report their national data. Member states are expected to report their numbers twice a week.

As a result, the tracker indicated the number of vaccine doses administered in its member states as of Monday was 8.23 million, though in reality the number is much higher.

(Not all countries had uploaded their data as February 2nd. )

According to AFP's own database compiled from official sources, by 1600 GMT Monday, at least 12.6 million doses have been administered to 10.5 million people in the EU, representing 2.3 percent of the population.

“In this early phase of vaccination campaigns, monitoring the number of doses distributed to countries and doses received by individuals provides useful insights into the progress of vaccine deployment and the evolution of vaccination campaigns,” the ECDC said in a statement.

“It also provides initial indicative estimates of vaccine uptake for the first and second dose per population targeted by vaccine recommendations on the national level.”

ECDC Director Andrea Ammon said: “It is with great pleasure that we launch the Vaccine Tracker that provides a near-live view on vaccination progress in Europe. Vaccination campaigns are not to be viewed merely as a race for the largest numbers at the quickest speed. As the rollout progresses, vaccination strategies will need to be flexible and adaptable.”

Move away from AstraZeneca

The European Commission indicated Monday that it is shifting its early Covid-19 vaccination strategy away from AstraZeneca after the Anglo-Swedish company fell far short in its delivery of doses.

The head of the Commission's health directorate, Sandra Gallina, told MEPs the firm has been able to guarantee just 25 percent of the more than 100 million doses promised and that this was “a real issue” for the EU's 27 countries.

“AstraZeneca was going to be the mass vaccine for quarter one,” she said, referring to the first three months of 2021. “The fact that AstraZeneca is not there in the quantities that were stipulated in the contract is quite problematic for all member states.”

Galina added that the Commission was now looking to the vaccines made by BioNTech/Pfizer and Johnson & Johnson to fill the gap.

“There will be many more quantities in quarter two because there will be a new contract that will spring into action. So we will not have only BioNTech and Moderna but we will have BioNTech with a new contract, so it's double the quantities.”

She noted that the new mRNA technology used in the BioNTech/Pfizer vaccine and a similar one by Moderna had shown “impressive” efficacy levels of over 90 percent in immunising against Covid.

AstraZeneca, which uses the adenovirus technique, has 60 percent efficacy, according to clinical data parsed by the European Medicines Agency.

Gallina said production of the BioNTech/Pfizer doses could be ramped up using other pharmaceutical companies' facilities, for instance ones offered by French company Sanofi, whose own vaccine bid has hit obstacles. 

“Manufacturing is really the moment when we have a problem of constraint for the vaccines,” Gallina said.

But she emphasised that “the problem will not be having the vaccines, the problem will be vaccination… We need to quickly look at how we can speed up vaccination once the vaccines are there.”

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

COVID-19

France scraps compulsory self-isolation after positive Covid test

France's public health body has outlined how Covid-19 rules will change on February 1st, including an end to compulsory self-isolation after a positive test result.

France scraps compulsory self-isolation after positive Covid test

Starting on February 1st, Covid rules will relax in France as the country ends compulsory isolation for those who test positive for the virus.

However, those travelling from China to France will still be required to agree to a random screening upon arrival and to isolate in the case of a positive Covid-19 test result. Travellers aged 11 and over coming from China must also provide a negative test result (less tan 48 hours) prior to boarding and those aged six and over must agree to wear a mask on board flights. These regulations – which was set to last until January 31st – is set to remain in place until February 15th.

The French public health body (The Direction générale de la santé or DGS)  announced the change on Saturday in a decree published in the “Journal Officiel” outlining the various ways the body will loosen previous coronavirus restrictions.

READ MORE: What Covid rules and recommendations remain for visiting France?

Those who were in contact with someone who tested positive – ie a contact cases – will also no longer be required to take a test, though the public health body stressed that both testing after contact and isolating after receiving a positive test remain recommended.

Previously, even asymptomatic people who had been in contact with someone who tested positive for Covid-19 were required to test on the second day after being notified that they were a “contact-case”.

These changes will take effect on February 1st.

READ MORE: What changes in France in February 2023?

The DGS also said that website SI-DEP, which records test results, will remain in operation until June 30th, however starting in February it will only collect personal data with the express permission of the patient.

Manual widget for ML (class=”ml-manual-widget-container”)

Additionally, the French government announced that sick leave procedures for people with Covid-19 will return to normal on February 1st – this means that those who test positive for Covid-19 will have the three-day wait period before daily sick benefits are required to be paid, as is usually the case. Previously, people with Covid-19 could expect daily sick benefits to begin at the start of their sick leave period (arrêt maladie in French).  

READ MORE: How sick leave pay in France compares to other countries in Europe

Covid tests are still available on walk-in basis from most pharmacies are are free to people who are fully vaccinated and registered in the French health system. Unvaccinated people, or visitors to France, have to pay up to a maximum of €22 for an antigen test of €49 for a PCR test. 

If you recently tested positive for Covid-19 in France – or you suspect you may have contracted Covid-19 – you can find some information for how to proceed here.

In explaining the changes that will begin in February, the French public health body also noted a drop in Covid-19 infections in the past month. As of January 30th, approximately 3,800 people in France had tested positive in the previous 24 hours for the coronavirus – which represents a decrease from the averages of 20,000 new cases per day about one month ago.

SHOW COMMENTS